Tandler, C.; Schmidt, M.; Heitmann, J.S.; Hierold, J.; Schmidt, J.; Schneider, P.; Dörfel, D.; Walz, J.; Salih, H.R.
Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia. Cancers 2020, 12, 2725.
https://doi.org/10.3390/cancers12102725
AMA Style
Tandler C, Schmidt M, Heitmann JS, Hierold J, Schmidt J, Schneider P, Dörfel D, Walz J, Salih HR.
Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia. Cancers. 2020; 12(10):2725.
https://doi.org/10.3390/cancers12102725
Chicago/Turabian Style
Tandler, Claudia, Moritz Schmidt, Jonas S. Heitmann, Julia Hierold, Jonas Schmidt, Pascal Schneider, Daniela Dörfel, Juliane Walz, and Helmut R. Salih.
2020. "Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia" Cancers 12, no. 10: 2725.
https://doi.org/10.3390/cancers12102725
APA Style
Tandler, C., Schmidt, M., Heitmann, J. S., Hierold, J., Schmidt, J., Schneider, P., Dörfel, D., Walz, J., & Salih, H. R.
(2020). Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia. Cancers, 12(10), 2725.
https://doi.org/10.3390/cancers12102725